232 related articles for article (PubMed ID: 21529178)
21. Meningiomas and neurofibromatosis for the oncologist.
Schrell UM; Fahlbusch R; Adams EF
Curr Opin Oncol; 1994 May; 6(3):247-53. PubMed ID: 8080853
[TBL] [Abstract][Full Text] [Related]
22. Familial meningioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases.
Maxwell M; Shih SD; Galanopoulos T; Hedley-Whyte ET; Cosgrove GR
J Neurosurg; 1998 Mar; 88(3):562-9. PubMed ID: 9488313
[TBL] [Abstract][Full Text] [Related]
23. Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes.
Zhang X; Jia H; Lu Y; Dong C; Hou J; Wang Z; Wang F; Zhong H; Wang L; Wang K
Discov Med; 2014 Dec; 18(101):301-311. PubMed ID: 25549701
[TBL] [Abstract][Full Text] [Related]
24. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
25. Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
Domingues P; González-Tablas M; Otero Á; Pascual D; Ruiz L; Miranda D; Sousa P; Gonçalves JM; Lopes MC; Orfao A; Tabernero MD
Oncotarget; 2015 May; 6(13):10671-88. PubMed ID: 25965831
[TBL] [Abstract][Full Text] [Related]
26. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
27. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
28. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
Birzu C; Peyre M; Sahm F
Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
[TBL] [Abstract][Full Text] [Related]
29. Related mechanisms, current treatments, and new perspectives in meningioma.
Inetas-Yengin G; Bayrak OF
Genes Chromosomes Cancer; 2024 May; 63(5):e23248. PubMed ID: 38801095
[TBL] [Abstract][Full Text] [Related]
30. Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas.
Cordova C; Kurz SC
Curr Oncol Rep; 2020 Jul; 22(8):84. PubMed ID: 32617743
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathogenesis of meningiomas.
Perry A; Gutmann DH; Reifenberger G
J Neurooncol; 2004 Nov; 70(2):183-202. PubMed ID: 15674477
[TBL] [Abstract][Full Text] [Related]
32. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic features of meningiomas.
Makashova ES; Lasunin NV; Galkin MV; Zolotova SV; Karandasheva KO; Golanov AV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(4):101-106. PubMed ID: 37650282
[TBL] [Abstract][Full Text] [Related]
34. Meningioma genomics: a therapeutic challenge for clinicians.
Moussalem C; Massaad E; Minassian GB; Ftouni L; Bsat S; Houshiemy MNE; Alomari S; Sarieddine R; Kobeissy F; Omeis I
J Integr Neurosci; 2021 Jun; 20(2):463-469. PubMed ID: 34258948
[TBL] [Abstract][Full Text] [Related]
35. Current treatment of meningiomas.
McDermott MW
Curr Opin Neurol; 1996 Dec; 9(6):409-13. PubMed ID: 9007396
[TBL] [Abstract][Full Text] [Related]
36. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma.
Harada T; Irving RM; Xuereb JH; Barton DE; Hardy DG; Moffat DA; Maher ER
J Neurosurg; 1996 May; 84(5):847-51. PubMed ID: 8622160
[TBL] [Abstract][Full Text] [Related]
37. Preoperative Embolization of Skull Base Meningiomas: Outcomes in the Onyx Era.
Przybylowski CJ; Baranoski JF; See AP; Flores BC; Almefty RO; Ding D; Chapple KM; Sanai N; Ducruet AF; Albuquerque FC
World Neurosurg; 2018 Aug; 116():e371-e379. PubMed ID: 29751190
[TBL] [Abstract][Full Text] [Related]
38. Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
van Tilborg AA; Morolli B; Giphart-Gassler M; de Vries A; van Geenen DA; Lurkin I; Kros JM; Zwarthoff EC
J Pathol; 2006 Mar; 208(4):564-73. PubMed ID: 16353169
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of petroclival meningiomas: current state of the problem].
Shimanskiy VN; Karnaukhov VV; Galkin MV; Tanyashin SV; Golanov AV; Poshataev VK; Shevchenko KV
Zh Vopr Neirokhir Im N N Burdenko; 2019; 83(6):78-89. PubMed ID: 32031171
[TBL] [Abstract][Full Text] [Related]
40. The cytogenetic relationship between primary and recurrent meningiomas points to the need for new treatment strategies in cases at high risk of relapse.
Espinosa AB; Tabernero MD; Maíllo A; Sayagués JM; Ciudad J; Merino M; Alguero MC; Lubombo AM; Sousa P; Santos-Briz A; Orfao A
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):772-80. PubMed ID: 16467088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
